Doctor Reviews Cagrisema: New Boosted Ozempic!
A short physician explainer on CagriSema, a combination of semaglutide and cagrilintide, comparing its weight loss and nausea figures with semaglutide and tirzepatide.
Key moments
Tap a moment to play the video from there.
- 0:00Introducing CagriSema and the video planDr Kidd introduces himself as a general practitioner and says he will explain how CagriSema works and compare it with semaglutide and tirzepatide.
- 0:30How semaglutide and tirzepatide workHe describes semaglutide as a GLP1 agonist and tirzepatide as a dual GLP1 and GIP agonist.
- 1:01CagriSema's two active ingredientsHe explains that CagriSema pairs semaglutide with cagrilintide, which he describes as acting on amylin and calcitonin receptors.
- 1:32Calcitonin and the weight loss comparisonHe says calcitonin also affects appetite through brain receptors, then begins comparing weight loss data, starting with about 15% for semaglutide at 2.4 mg.
- 2:02Tirzepatide results and dropout figuresHe cites about 20% average loss at 72 weeks for tirzepatide 15 mg and explains why the graph shows both 22.5% and 20.9%.
- 2:30CagriSema trial weight loss resultsHe reports 20.4% average loss at 68 weeks in a 3,417 adult study, rising to 22.7% among completers, and calls it similar to tirzepatide.
- 3:02Nausea and vomiting rates comparedHe says CagriSema had the highest nausea (55%) and vomiting (26.1%) rates, ahead of semaglutide and tirzepatide.
- 4:03Summary and availabilityHe concludes CagriSema is among the strongest options but has more nausea and vomiting, and says it was not yet commercially available when recorded.
What the video says
Dr Kidd, an Australian general practitioner, uses this 4.5 minute video to explain CagriSema and compare it with two existing GLP-1 based weight loss drugs. He says he has helped thousands of patients with weight loss, and he frames the video around whether CagriSema is the best of the three.
He first describes the background. Semaglutide mimics the hormone GLP1, and tirzepatide is a dual GLP1 and GIP agonist. He then presents CagriSema as a different kind of combination: semaglutide plus cagrilintide, which he describes as a newer compound acting on amylin and calcitonin receptors. He says amylin slows how fast food leaves the stomach and sends satiety signals to the brain, and that calcitonin, usually known for calcium and bone regulation, also affects appetite through brain receptors.
The middle section is a results comparison. For semaglutide at 2.4 mg he cites average weight loss of about 15% after roughly a year. For tirzepatide at 15 mg he cites about 20% at 72 weeks, and he explains the gap between 22.5% (without dropouts) and 20.9% (with dropouts), choosing 20.9% as his conservative figure. For CagriSema he describes a study of 3,417 adults with obesity or overweight, reporting 20.4% weight loss at 68 weeks including dropouts and 22.7% among completers. He concludes it looks better than semaglutide alone and similar to tirzepatide.
He then turns to side effects. He reports that CagriSema had the highest rates of nausea (55%) and vomiting (26.1%), compared with about 30% and 17% for semaglutide and about 23% and 9% for tirzepatide. He adds that most patients who get these effects are generally able to tolerate them and continue.
His summary is that CagriSema is among the strongest weight loss medications on current data, with nausea and vomiting as its main weakness. He notes it was not commercially available at the time of recording and that regulatory review and real world long term data are still needed.
On each compound
CagriSema1:01
Dr Kidd describes CagriSema as a combination of semaglutide and cagrilintide. He reports 20.4% average weight loss at 68 weeks (22.7% among completers) and the highest nausea and vomiting rates of the three drugs, and says it was not yet commercially available.
See how your DNA reads CagriSemaSemaglutide0:30
Dr Kidd describes semaglutide as a GLP1 agonist. He cites about 15% average weight loss after roughly a year at 2.4 mg, with nausea around 30% and vomiting around 17% on average.
See how your DNA reads SemaglutideTirzepatide0:30
Dr Kidd describes tirzepatide as a dual GLP1 and GIP agonist. He cites about 20.9% average weight loss at 72 weeks on 15 mg, with nausea around 23% and vomiting around 9%.
See how your DNA reads TirzepatideCagrilintide1:01
Dr Kidd describes cagrilintide as a newer compound acting as an amylin and calcitonin receptor agonist. He says amylin slows stomach emptying and signals satiety, and calcitonin affects appetite through brain receptors.
See how your DNA reads CagrilintideWhat this video doesn’t settle
- The video relies on cross-trial comparisons of separate studies, so it does not establish how the three drugs compare in a head-to-head trial.
- It gives no trial names, doses for CagriSema or participant details beyond the 3,417 adults, and the figures come from on-screen graphs the speaker reads out.
- Long term safety and real world performance of CagriSema are explicitly left open by the speaker.
Questions this video answers
What is CagriSema made of?
Dr Kidd says CagriSema combines semaglutide, a GLP1 agonist, with cagrilintide, which he describes as an amylin and calcitonin receptor agonist. He contrasts this with tirzepatide, which combines two incretin hormones.
How much weight loss did CagriSema show compared with semaglutide and tirzepatide?
Dr Kidd cites 20.4% average weight loss at 68 weeks for CagriSema (22.7% among completers). That compares with about 15% for semaglutide and 20.9% for tirzepatide. He concludes it beats semaglutide alone and looks similar to tirzepatide.
Does CagriSema cause more nausea than other GLP-1 drugs?
According to Dr Kidd, it did: 55% of patients reported nausea and 26.1% vomiting. He cites about 30% and 17% for semaglutide and about 23% and 9% for tirzepatide, and says most affected patients are generally able to continue.
Is CagriSema available to patients yet?
Dr Kidd says it was not commercially available when he recorded the video. He says regulatory review and long term real world data are still needed to confirm the findings.
Video by Dr Kidd on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
